MMAF (Hydrochloride), or Monomethyl Auristatin F Hydrochloride, is a synthetic compound primarily used in the field of medicinal chemistry, particularly in the development of antibody-drug conjugates (ADCs) for cancer therapy. It is a potent microtubule inhibitor derived from the natural product dolastatin 10, which disrupts the mitotic spindle formation, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. As a hydrochloride salt, MMAF exhibits improved solubility and stability in aqueous solutions, making it suitable for pharmaceutical formulations. The compound is characterized by its high potency and specificity, which allows for targeted delivery to tumor cells while minimizing effects on normal tissues. Its mechanism of action involves binding to tubulin, thereby inhibiting polymerization and disrupting microtubule dynamics. Due to its cytotoxic properties, MMAF is being investigated in various clinical settings, and ongoing research aims to optimize its efficacy and safety profiles in combination with monoclonal antibodies for enhanced therapeutic outcomes in oncology.

MMAF (Hydrochloride)

1415246-68-2: MMAF (Hydrochloride), or Monomethyl Auristatin F Hydrochloride, is a synthetic compound primarily used in the field of medicinal chemistry, particularly in the development of antibody-drug conjugates (ADCs) for cancer therapy. It is a potent microtubule inhibitor derived from the natural product dolastatin 10, which disrupts the mitotic spindle formation, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. As a hydrochloride salt, MMAF exhibits improved solubility and stability in aqueous solutions, making it suitable for pharmaceutical formulations. The compound is characterized by its high potency and specificity, which allows for targeted delivery to tumor cells while minimizing effects on normal tissues. Its mechanism of action involves binding to tubulin, thereby inhibiting polymerization and disrupting microtubule dynamics. Due to its cytotoxic properties, MMAF is being investigated in various clinical settings, and ongoing research aims to optimize its efficacy and safety profiles in combination with monoclonal antibodies for enhanced therapeutic outcomes in oncology.

<p>MMAF HCl, used in ADCs like Vorsetuzumab, inhibits tubulin polymerization, serving as an antitumor agent.</p>

CAS 1415246-68-2

MMAF (Hydrochloride)

MMAF Hydrochloride

Ref: TM-T16121